Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4250894
Max Phase: Preclinical
Molecular Formula: C20H19N5OS
Molecular Weight: 377.47
Molecule Type: Small molecule
Associated Items:
ID: ALA4250894
Max Phase: Preclinical
Molecular Formula: C20H19N5OS
Molecular Weight: 377.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(Nc1cccc2ncsc12)N1CCN(c2cccc3[nH]ccc23)CC1
Standard InChI: InChI=1S/C20H19N5OS/c26-20(23-17-5-1-4-16-19(17)27-13-22-16)25-11-9-24(10-12-25)18-6-2-3-15-14(18)7-8-21-15/h1-8,13,21H,9-12H2,(H,23,26)
Standard InChI Key: FHXPZOILFJDFHI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 377.47 | Molecular Weight (Monoisotopic): 377.1310 | AlogP: 4.13 | #Rotatable Bonds: 2 |
Polar Surface Area: 64.26 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.85 | CX Basic pKa: 3.07 | CX LogP: 3.30 | CX LogD: 3.30 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.55 | Np Likeness Score: -1.60 |
1. Anglin J, Zavareh RB, Sander PN, Haldar D, Mullarky E, Cantley LC, Kimmelman AC, Lyssiotis CA, Lairson LL.. (2018) Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma., 28 (16): [PMID:29731362] [10.1016/j.bmcl.2018.04.061] |
Source(1):